Opinion|Videos|July 17, 2024
Treatment in Early Relapse Multiple Myeloma: Takeaways from EHA 2024
Author(s)Joseph Mikhael, MD
Dr. Mikhael discusses treatment in early relapse of multiple myeloma.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- Please discuss recent updates presented at EHA 2024 in early-relapse multiple myeloma from CARTITUDE-4, KARMMA-2, DREAMM-7, and DREAMM-8.
Advertisement
Related to this article
Non-CF bronchiectasis prevalence rose across commercial, Medicare, and Medicaid plans from 2016 to 2024, while incidence stayed relatively stable.
Shorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.
Low awareness that fatty liver can silently progress and that MASH fibrosis is treatable drives missed follow-up testing, says Rohit Loomba, MD.
A prospective Italian study of 492 postmenopausal women found ultrasound signs of deep endometriosis in 7.3%, often plaque-like and poorly vascularized.
AHIP's Jeanette Thornton explains where 2027 prior authorization standards fit in the affordability debate and what plans want from Congress.
A new tool puts this year's measles toll at nearly $83 million as global health experts weigh whether the US has lost elimination status.
Earlier Alzheimer disease detection is outpacing specialist capacity and may widen gaps for underserved patients, Cleveland experts say.
Young adults with cancer symptoms often fall outside screening guidelines, face costly imaging, and go undiagnosed longer, oncologists say.
Advertisement
Advertisement
Trending on AJMC
1
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
2
How Plans, Clinicians Should Handle Gray-Market Retatrutide
3
Early-Onset Cancers Often Found Late as Screening Gaps Persist
4
FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat Stroke
5